Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes

Diabetes and Metabolism

Volumn 32, Issue 1, 2006, Pages 69-76

  Palmer, A J ^a   Chen, R ^b   Valentine, W J ^a   Roze, S ^a   Bregman, B ^b   Mehin, N ^c   Gabriel, S ^c  

^a IQVIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c SANOFI   (France)

Author keywords

Cost effectiveness; Hypertension; Nephropathy; Screening; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; IRBESARTAN;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SIMULATION; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; MEDICAL ASSESSMENT; MICROALBUMINURIA; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; SCREENING TEST; STATISTICAL ANALYSIS; URINALYSIS; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHY; ECONOMICS; FRANCE; HYPERTENSION; INCIDENCE; MIDDLE AGED; MORTALITY; PROBABILITY;

ADULT; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FRANCE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PROBABILITY;

EID: 33646117518     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70249-5     Document Type: Article

References (37)

1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
2. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76
3. Smitten A, Rodby RA, Chen RS. The increasing prevalence of microalbuminuria in the United States: data from the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and NHANES 1999-2000. J Am Soc Nephrol 2003;14(suppl. 1):682 [Abstract]
4. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808
5. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000;14:667-85
6. Charpentier G, Genes N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003;29:152-58
7. Fagnani F, Souchet T, Labed D, Gaugris S, Hannedouche T, Grimaldi A. Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France-2001). Diabetes Metab 2003;29:58-64
8. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S5-12
9. Charra B, VoVan C, Marcelli D, et al. Diabetes mellitus in Tassin, France: remarkable transformation in incidence and outcome of ESRD in diabetes. Adv Ren Replace Ther 2001;8:42-56
10. Gourdy P, Ruidavets JB, Ferrieres J, et al. Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions - The MONICA study 1995-97. Diabetes Metab 2001;27:347-58
11. Ricordeau P, Weill A, Vallier N, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003;29:497-504
12. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S1-85
13. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:910-12
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
16. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004;27:1897-903
17. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
18. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier D. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003;18:2059-66
19. World Health Organization. Life tables for 191 countries. World mortality in 2000 (http://www3.who.int/whosis/life_tables/life_tables.cfm?path=evidence, life_tables&language=english)
20. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;24:447-53
21. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
22. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-65
23. Combe C, Chauveau P, Laville M, et al. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis 2001;37:S81-8
24. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System Annual Report: Atlas of End-Stage Renal Disease in the United States. Bethesda: USRDS, 2001
25. IMS Health. Age distribution of oral antidiabetics by prescription year ending June 2000 (www.ims-global.com)
26. The Royal College of General Practitioners Effective Clinical Practice Unit. Clinical guidelines for type 2 diabetes. Renal disease: prevention and early management. Sheffield: University of Sheffield 2002 (www.shef.ac.uk/ guidelines)
27. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
28. Agence Française de Sécurité Sanitaire des Produits de Santé (AFS-SAPS) Dictionnaire Vidal, L'information de référence sur les produits de santé. Issy Les Moulineaux : Vidal 2004
29. Cogny F, Ngohou C, Ponterfact R, Bacquart-Dufour K, Riberi P, eds. Insuffisiance rénale terminale. Gestions Hospitalières. Vitry-sur-Seine: Heral, 1995
30. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000;14:18-24
31. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
32. Tam TYH, Dix Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10:5-15
33. Ritz E. Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 2005;20:21-5
34. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993;306:1722-5
35. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995;25:107-12
36. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9
37. Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 1998;31:49-54